2,557
Views
3
CrossRef citations to date
0
Altmetric
Gastroenterology

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1302-1310 | Received 26 May 2020, Accepted 21 Jul 2020, Published online: 13 Aug 2020

Figures & data

Figure 1. Markov model. Abbreviation. CDAI, Crohn’s disease activity index.

Figure 1. Markov model. Abbreviation. CDAI, Crohn’s disease activity index.

Table 1. Input parameters.

Table 2. Result of base-case analysis.

Figure 2. Cost-effectiveness acceptability curve comparing between four regimens. Abbreviations. IFX, infliximab; WTP, willingness-to-pay; USD, United State dollars.

Figure 2. Cost-effectiveness acceptability curve comparing between four regimens. Abbreviations. IFX, infliximab; WTP, willingness-to-pay; USD, United State dollars.

Table 3. Result of budget impact of base-case analysis in adult patients with moderate-to-severe Crohn’s disease.

Supplemental material

Supplemental Material

Download PDF (1.1 MB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.